Cronos Cannabis Company Slashes Losses, Reports Highest Quarterly Net Revenue In Q1 2024
Benzinga (Thu, 9-May 1:18 PM ET)
Cronos Group Soars with Robust Q1 Earnings
TipRanks (Thu, 9-May 8:29 AM ET)
Cronos Group beats top-line and bottom-line estimates; reaffirms FY24 outlook
Seeking Alpha News (Thu, 9-May 8:06 AM ET)
Cronos Group Reports 2024 First Quarter Results
Globe Newswire (Thu, 9-May 7:30 AM ET)
Cronos Enters United Kingdom Cannabis Market
Globe Newswire (Tue, 7-May 7:00 AM ET)
Cronos Group Inc. to Hold Virtual 2024 Annual Meeting of Shareholders
Globe Newswire (Fri, 26-Apr 4:45 PM ET)
Cronos Group Inc. to Hold 2024 First Quarter Earnings Conference Call on May 9, 2024
Globe Newswire (Thu, 25-Apr 4:15 PM ET)
Cannabis Market Flourishes Amid Global Legalization, Driving Concerns About Road Safety
Globe Newswire (Mon, 22-Apr 9:30 AM ET)
Cronos Launches Lord Jones Chocolate Fusions
Globe Newswire (Mon, 25-Mar 7:00 AM ET)
Cronos Group Inc. to Speak at the 36th Annual Roth Conference
Globe Newswire (Tue, 12-Mar 4:15 PM ET)
Cronos Group, headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S. the company has an option to acquire 10.5% of U.S. multistate operator PharmaCann upon easing of federal prohibition.
Cronos Group - Common Share trades on the NASDAQ stock market under the symbol CRON.
As of May 14, 2024, CRON stock price climbed to $3.05 with 2,263,728 million shares trading.
CRON has a beta of 1.14, meaning it tends to be more sensitive to market movements. CRON has a correlation of 0.07 to the broad based SPY ETF.
CRON has a market cap of $1.17 billion. This is considered a Small Cap stock.
Last quarter Cronos Group - Common Share reported $25 million in Revenue and -$.01 earnings per share. This beat revenue expectation by $2 million and met earnings estimates .
In the last 3 years, CRON stock traded as high as $9.42 and as low as $1.64.
The top ETF exchange traded funds that CRON belongs to (by Net Assets): YOLO, ONEQ, TOKE, DFIC, DISV.
CRON has outperformed the market in the last year with a price return of +76.3% while the SPY ETF gained +28.3%. CRON has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +44.5% and +19.6%, respectively, while the SPY returned +5.9% and +2.2%, respectively.
CRON support price is $2.80 and resistance is $3.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CRON stock will trade within this expected range on the day.